The present invention refers to chromogranin A-derived peptides that are potent dual ligands for integrins αvβ6 and avβ8, their therapeutic and diagnostic uses and relative compositions.

The present invention refers to chromogranin A-derived peptides that are potent dual ligands for integrins αvβ6 and avβ8, their therapeutic and diagnostic uses and relative compositions.

Systems, kits and methods for preparing an injection system and/or treating target lesions with a selective internal radiation therapy which includes a double-barrel syringe loaded with a two-component tissue glue and radioisotope loaded microspheres. The microspheres are loaded into the syringe based on the size of the target location and are administered with a needle or dual-lumen catheter. Dosing regimens for treating breast cancer lesions or surgical beds up to 130 mm in diameter and hepatocellular carcinoma lesions up to 50 mm are included.

The present invention relates to methods for radiolabelling GRPR antagonists such as NeoB, and their kits. In particular, the invention to a method for labeling a gastrin-releasing peptide receptor (GRPR) antagonist with a radioactive isotope, preferably .sup.68Ga, .sup.67Ga or .sup.64Cu, said method comprising the steps of: i. providing a first vial comprising said GRPR antagonist in dried form, ii. adding a solution of said radioactive isotope into said first vial, thereby obtaining a solution of said GRPR antagonist with said radioactive isotope, iii. mixing the solution obtained in ii. with at least a buffering agent and incubating it for a sufficient period of time for obtaining said GRPR antagonist labeled with said radioactive isotope, and, iv. optionally, adjusting the pH of the solution.

The invention relates to water soluble .sup.18F-prosthetic groups and the synthesis and use of .sup.18F-labeled biological molecules containing the .sup.18F-prosthetic groups for imaging various processes within the body, for detecting the location of molecules associated with disease pathology, and for monitoring disease progression are disclosed.

A method for producing an .sup.225Ac solution includes a step (I) of irradiating a .sup.226Ra target with particles to generate two or more actinium radioisotopes (Ac) including at least .sup.225Ac, a step (II) of dissolving the .sup.226Ra target after the aforementioned step to obtain a solution (1), a step (III) of separating .sup.226Ra and Ac contained in the solution (1) to obtain a solution (2), a step (IV) of allowing Ac contained in the solution (2) other than .sup.225Ac to decay to obtain a solution (3), and a step (V) of separating Ra and Ac contained in the solution (3) to obtain a solution (4). The solution (4) is used to produce a medicine that contains, as an active ingredient, a conjugate between a chelating agent that has formed a complex with .sup.225Ac, and a targeting agent.

Kits for the preparation, synthesis, and delivery of compositions comprising a conjugate of a nucleoside analog, a chelator, and a label for use as imaging and therapeutic agents. The kits, as well as methods for their use, may be used in diagnosing, treating, or monitoring the progression of infectious diseases and/or symptoms or complications resulting from infection.

The present invention provides peptides and peptide-conjugates that bind to α.sub.vβ.sub.6 integrin. The peptide-conjugates can be used for a variety of imaging and therapeutic applications. Methods of use and peptide optimization are also provided herein.

The present invention provides peptides and peptide-conjugates that bind to α.sub.vβ.sub.6 integrin. The peptide-conjugates can be used for a variety of imaging and therapeutic applications. Methods of use and peptide optimization are also provided herein.

A compound comprising a prostate specific membrane antigen (PSMA)-targeting moiety of the following formula or of a salt or a solvate thereof. R.sup.0 is O or S. Each of R.sup.1a, R.sup.1b and R.sup.1c may be —CO.sub.2H, —SO.sub.2H, —SO.sub.3H, —PO.sub.2H, or —PO.sub.3H.sub.2, for example. R.sup.2 may be methylene or a derivative thereof, propylene or a derivative thereof, or a derivative of ethylene, optionally substituted. R.sup.3 is a linker. When the PSMA-targeting moiety is linked to a radiolabeling group, the compound may be used as an imaging agent or therapeutic agent for PSMA-expressing diseases/conditions. ##STR00001##